Natalizumab improves disability on the Multiple Sclerosis Functional Composite in a randomised, double-blind, placebo-controlled study of patients with relapsing multiple sclerosis

被引：0
|
作者：
Munschauer, F.
Giovannoni, G.
O'Connor, P. W.
Phillips, J. T.
Polman, C. H.
Pace, A.
Hyde, R.
Kim, R.
机构：
[1] Jacobs Neurol Inst, Buffalo, NY USA
[2] Barts & London Queen Marys Sch Med & Dent, London, England
[3] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[4] Multiple Sclerosis Ctr Texas Neurol, Dallas, TX USA
[5] VU Med Ctr, Amsterdam, Netherlands
[6] Biogen Idec Inc, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S124 / S125
页数：2
相关论文
共 50 条
  • [41] GLANCE: A double-blind, randomized, placebo-controlled, parallel-group safety study of natalizumab in combination with glatiramer acetate in subjects with relapsing-remitting multiple sclerosis
    Goodman, AD
    Rossman, HS
    Bar-Or, A
    Miller, A
    Miller, D
    Lublin, F
    Khan, O
    Metz, L
    Panzara, M
    Yang, MH
    Toal, M
    Sandrock, A
    [J]. NEUROLOGY, 2005, 64 (06) : A277 - A278
  • [42] Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial
    Rahimlou, Mehran
    Nematollahi, Shima
    Husain, Durdana
    Banaei-Jahromi, Nasrin
    Majdinasab, Nastaran
    Hosseini, Seyed Ahmad
    [J]. FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [43] Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: a categorical disability trend analysis
    Liu, C
    Blumhardt, LD
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2002, 8 (01) : 10 - 14
  • [44] Baseline demographics of a placebo-controlled, double-blind, randomised study of oral laquinimod 0.6mg in treating relapsing-remitting multiple sclerosis: the ALLEGRO study
    Comi, G.
    Jeffery, D.
    Kappos, L.
    Montalban, X.
    Boyko, A. N.
    Filippi, M.
    [J]. MULTIPLE SCLEROSIS, 2009, 15 (09): : S127 - S127
  • [45] Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study
    Achiron, Anat
    Givon, Uri
    Magalashvili, David
    Dolev, Mark
    Zaltzman, Sigal Liraz
    Kalron, Alon
    Stern, Yael
    Mazor, Zeev
    Ladkani, David
    Barak, Yoram
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 767 - 775
  • [46] A randomised, placebo-controlled, double-blind, multicentre, phase IIIb study assessing efficacy, safety and tolerability of Rebiff® New Formulation in patients with relapsing-remitting multiple sclerosis
    De Stefano, N.
    Beelke, M.
    [J]. JOURNAL OF NEUROLOGY, 2007, 254 : 191 - 191
  • [47] Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
    Comi, G.
    Pulizzi, A.
    Rovaris, M.
    Abramsky, O.
    Arbizu, T.
    Boiko, A.
    Gold, R.
    Havrdova, E.
    Komoly, S.
    Selmaj, K. W.
    Sharrack, B.
    Filippi, M.
    [J]. LANCET, 2008, 371 (9630): : 2085 - 2092
  • [48] Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: results of a 6-month, randomised, double-blind, placebo-controlled, phase 2 study
    Saida, T.
    Kikuchi, S.
    Itoyama, Y.
    Hao, Q.
    Kurosawa, T.
    Nagato, K.
    Tsumiyama, I.
    Zhang-Auberson, L.
    Kira, J. -I.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S418 - S419
  • [49] Pharmacokinetics and pharmacodynamics of PEGylated interferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized double-blind placebo-controlled study
    Boyko, A.
    Alifirova, V.
    Boyko, O.
    Greshnova, I.
    Zaslavskiy, L.
    Zakharova, M.
    Parshina, E.
    Poverennova, I.
    Sazonov, D.
    Sokolova, I.
    Shur, S.
    Bakhtiyarova, K.
    Dudin, V.
    Khabirov, F.
    Zinkina-Orikhan, A.
    Linkova, Y.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 911 - 911
  • [50] Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study
    J. C. Bertoglio
    M. Baumgartner
    R. Palma
    E. Ciampi
    C. Carcamo
    D. D. Cáceres
    G. Acosta-Jamett
    J. L. Hancke
    R. A. Burgos
    [J]. BMC Neurology, 16
12345